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Perturbations of the epigenomic landscape, as defined by
genome-wide localization of histone post-translational mod-
ifications, DNA methylations and chromatin regulatory
proteins, have been increasingly appreciated as a common
feature of cancer. While epigenetic changes were previ-
ously argued as merely a consequence of the cancerous
state, recent evidence collectively points to a perception that
altered epigenetic states may play a causal role in cancer
development (Brien et al., 2016). In fact, cancer genome
sequencing studies have shown that genes encoding chro-
matin regulatory proteins are among the most commonly
mutated gene sets in cancer (Garraway and Lander, 2013).
In the meanwhile, 25%–30% of the identified cancer driver
mutations affect genes encoding chromatin regulatory pro-
teins (Vogelstein et al., 2013) and majority of these somatic
mutations are loss-of-function mutations, leading to a re-
duction or complete loss of chromatin-modifying activities
(Garraway and Lander, 2013). Nowadays, it has been widely
recognized that changes in epigenetic modifications pattern,
alike genetic mutations, play a driving role in cancer forma-
tion and persistence. Epigenetic regulators are required for
maintaining the expression of a set of key genes in cancer
cells, and disturbing this delicate balance may lead to cell
catastrophe, thereby connecting “epigenetic vulnerability” to
the paradigm of “oncogene addiction” (Brien et al., 2016).
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Moreover, different from genetic mutations caused function
loss that is hard to target, the dynamic nature of epigenetic
programming is often reversible by targeting distinct epige-
netic enzymes.
Global loss of histone acetylation is among the earliest
observed epigenetic abnormalities in cancer, and is asso-
ciated with unfavorable patient outcomes in certain cases
(Brien et al., 2016). Histone deacetylases (HDACs) cat-
alyze the removal of acetyl groups from lysine residues
in histone amino termini. Intervention of HDACs activ-
ity results in global increases in histone acetylation and
reverses aberrant epigenetic states in cancer (Figure 1)
(Nightingale et al., 2006; Thiagalingam et al., 2003). HDACs
in human consist of four classes, class I (HDAC1, HDAC2,
HDAC3 and HDAC8), class IIa (HDAC4, HDAC5, HDAC7
and HDAC9), class IIb (HDAC6 and HDAC10), class
III (sirtuins 1–7) and class IV (HDAC11). The majority
of HDAC inhibitors developed for anticancer therapy in-
hibits zinc-dependent class I, II and IV HDACs. Among
them, vorinostat (suberoylanilide hydroxamic acid, SAHA)
was firstly granted Food and Drug Administration (FDA)
approval for the treatment of advanced cutaneous T cell
lymphoma in 2006 (Mann et al., 2007). Since this initial
success, several HDACs inhibitors including romidepsin,
panobinostat, belinostat and chidamide have been proved
for the treatment of refractory cutaneous T cell lymphoma
(CTCL),  peripheral T-cell lymphoma (PTCL)  and multiple
Figure 1   HDACs involved regulation of histone acetylation modifications
and transcription activation.
myeloma (Brien et al., 2016). Over 25 HDAC inhibitors are
undergoing clinical trials for the potential benefit for different
types of cancer at the moment.
Despite the clinical progress of HDAC inhibitors, the
detailed mechanism by which HDAC inhibition impedes
cancer cell proliferation remains poorly understood. Elevated
histone acetylation levels have classically been associated
with locally decreased chromatin condensation and increased
accessibility for transcription factors (Brien et al., 2016).
However, this seems hardly explain the observation that
despite widespread hyperacetylation, HDAC inhibition often
causes site-specific chromatin remodeling. Recent studies
further reveal that specific histone acetylation marks operate
within a broader language of epigenetic modifications to
orchestrate the functions associated with chromatin, and are
dynamically maintained and read by trans-acting “writer”,
“eraser” and “reader” factors, in which HDACs function
as epigenetic erasers (Falkenberg and Johnstone, 2014;
Jenuwein and Allis, 2001). This leads to further aware-
ness of the epigenetic language encompassing histone and
DNA modifications, and provides mechanisms basis for
understanding the anticancer activity of HDAC inhibition.
In addition, it is necessary to mention that modulation of
the acetylation status of non-histone proteins, particularly
transcription factors (Falkenberg and Johnstone, 2014), also
contributes to the anticancer effects of HDAC inhibitors
(Figure 2).
With several agents approved for clinical use, HDACs in-
hibitors have been extensively explored in different cancer
types,  including multiple hematological malignancies  and 
a broad  range  of  solid  tumors.  At  the  moment,  a  major
Figure 2   Proposed mechanism of anticancer activity of HDACs inhibitors.
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unanswered question in the field is why HDAC inhibitors
have shown a preferential efficacy in subtypes of hemato-
logical malignancies (Mercurio et al., 2010). Most of the
HDACs inhibitors as single agent failed to show clinical
benefits in nearly all types of solid tumors, including breast
cancer, renal cancer, prostate cancer, and head and neck
cancer (Slingerland et al., 2014). Current studies tend to
combine HDACs inhibitors with chemotherapy or other
targeted therapies to explore for their utility in solid tu-
mors. Indeed, HDAC inhibitors have been combined with
a broad range of agents, both empirically and with rational
hypothesis-based approaches. For example, studies that
combine DNA methylation and HDAC inhibitors have been
initiated, with several clinical trials ongoing examining the
utility of these combinations in hematopoietic malignan-
cies and solid tumors (Falkenberg and Johnstone, 2014).
Regardless of varying degrees of success in hematopoietic
malignancies, it still lacks convincing evidence to conclude
the effectiveness in solid tumors. This question has spurred
increasing interest in the field, and very recent studies have
gained a glimpse of the mechanistic basis in subset of
cancer. Zeng et al. has shown that HDAC inhibition in-
creased the expression of leukemia inhibitory factor receptor
(LIFR) is a possible mechanism for their therapy failure in
breast cancer patients. Drug-induced feedback activation of
LIFR-STAT3 anti-apoptotic pathway arises from increased
histone acetylation of the LIFR promoter and its transcrip-
tional activation by the acetyllysine reader BRD4. Blocking
the resistance mechanism downstream using the approved
JAK inhibitor INCB018424 sensitized triple-negative breast
cancer (TNBC) cell lines and patient-derived xenografts to
vorinostat, suggesting that this combination therapy may
improve the clinical utility of HDAC inhibitors in TNBC
patients (Zeng et al., 2016). While this molecular basis and
derived therapeutic solutions still awaits clinical test, it is
predictable that this mechanism may not be applicable to
all solid tumors given the heterogeneous property of cancer.
Indeed, another study in non-small cell lung cancer (NSCLC)
models identifies a different mechanism that involves DNA
methyltransferase 1 (DNMT1) induced hypermethylation of
insulin-like growth factor 2, which may account for primary
and acquired resistance to vorinostat. Co-targeting DNMT1
is shown to improve antitumor efficacy of HDAC inhibitors
in NSCLC (Min et al., 2016). These in-depth understanding
may promote the more strategic use of HDAC inhibitors
in combination with other agents, and expand the scope of
their clinical benefits. In parallel, other HDAC involved
combinations with therapeutic promise are identified us-
ing randomized screening and still lack strong mechanism
support. For example, the combination of HDAC with
inhibitors for PI3K or BET family proteins were shown
as potential therapeutic solutions for MYC-driven medul-
loblastoma or pancreatic ductal adenocarcinoma respectively
(Mazur et al., 2015; Pei et al., 2016). The therapeutic value
revealed by these preclinical combination studies is worthy
clinical test and will undoubtedly take prominence in the
years to come.
In summary, our knowledge in mechanistic understand-
ing of the cancer epigenome has already delivered solid
successes to therapeutically manipulate cancer promoting
epigenetic states and cancer-associated gene expression
programs. However, our ability to intervene therapeutically
in this context is still limited (Brien et al., 2016). A better
understanding of the epigenomic alterations that promote
oncogenesis and their feedback response to targeted therapies
will be necessary to truly harness the therapeutic potential in
the manipulation of epigenetic regulation.
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